Data technologies to corner Antimicrobial resistance
Global impact of Data Technologies on AMR
Data Technologies will definitely impact the AMR space:
Artificial Intelligence & AMR
Machine learning – algorithms – deep learning in genomics, diagnostics and surveillance.
Artificial Intelligence is the use of machine learning and underlying algorithms to analyze big data as well as the use of deep learning with neural networks. Interesting applications include methods to identify and predict which genes cause infectious bacteria to become resistant to antibiotics, deep learning solutions like DeepARG to fight antibiotic resistance and whole genome sequencing with AI machine learning algorithms in combination with microbial resistance databases.
Internet of (Diagnostic) Things & AMR
Connected diagnostics – smartphone capabilities revolutionizing the fight against AMR
Internet of Things implies a network created from objects, which have the ability to communicate with other devices. The number of internet-connected objects could increase to somewhere between 20 and 100 billion by 2020. Appealing applications include connected diagnostics, wearables for remote patient monitoring and smartphone capabilities potentially revolutionizing the fight against AMR. Also think of future clinical development of novel antibiotics by point-of-care diagnostics and digital biomarkers to the patient.
Blockchain & AMR
Supply chain management antibiotics – smart sales contracts – prescription control (last resort) antibiotics – faster clinical trials of novel antibiotics.
Blockchain Technologies hold a distributed virtual ‘balance book’ in which transactions are bundled by using cryptography and further processed, validated and recorded. The approach enables secure and transparent processing of transactions. Relevant applications include supply chain management of (last resort) antibiotics and smart contracts to control the sales, prescription and the use of antibiotics. Also think of clinical trials of novel antibiotics whereby blockchain is key managing confidentiality of patient information and integrity of trial data. Also blockchain will facilitate new modes of collaboration and shorten the timelines for clinical development of novel antibiotics.
Interested in learning more? Join us on 5 June, 2019 in Amsterdam, The Netherlands:
